Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 6/20 | 0.52 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.46 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.46 |
| ▸ | ACP1 | P24666 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL89580 | 0.87 | NCF1 (0.49) | NCF1ACP1 | |
| SCHEMBL89579 | 0.87 | NCF1 (0.49) | NCF1ACP1 | |
| SCHEMBL30388617 | 0.87 | NCF1 (0.51) | NCF1AGTR1AGTR2 | |
| SCHEMBL23716946 | 0.84 | NCF1 (0.51) | NCF1AGTR1AGTR2 | |
| SCHEMBL30388939 | 0.84 | NCF1 (0.51) | NCF1AGTR1AGTR2 | |
| SCHEMBL8290938 | 0.82 | LMNA (0.58) | AGTR1AGTR2 | |
| SCHEMBL27795810 | 0.81 | NCF1 (0.51) | NCF1ACP1 | |
| SCHEMBL27774889 | 0.81 | NCF1 (0.43) | NCF1ACP1 | |
| SCHEMBL89578 | 0.80 | NCF1 (0.42) | NCF1ACP1 | |
| Hydrochloric Acid SCHEMBL2809059 | 0.79 | NCF1 (0.41) | NCF1ACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975252-B2 | Morpholine derivative | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-03-10 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | REN, AGTR1, AGTR2 | NCF1 4177/4885AGTR1 2/4885AGTR2 3/4885 |
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | NCF1 3515/4885AGTR1 3/4885AGTR2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.